Hot Features
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes wit... Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.02 | -1.44927536232 | 1.38 | 1.47 | 1.26 | 16648598 | 1.310231 | CS |
| 4 | 0.18 | 15.2542372881 | 1.18 | 1.47 | 1.08 | 15244861 | 1.24319756 | CS |
| 12 | -0.36 | -20.9302325581 | 1.72 | 1.8 | 1.08 | 14834824 | 1.40124411 | CS |
| 26 | 0.03 | 2.25563909774 | 1.33 | 2.01 | 1.08 | 15799921 | 1.4990321 | CS |
| 52 | -0.03 | -2.15827338129 | 1.39 | 2.01 | 1.04 | 11850453 | 1.42657604 | CS |
| 156 | -1.85 | -57.6323987539 | 3.21 | 5.34 | 1.04 | 10512480 | 2.34422891 | CS |
| 260 | -0.08 | -5.55555555556 | 1.44 | 5.34 | 0.9899 | 7907238 | 2.34055194 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.